Cibus Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cibus Inc reports Q2 loss, eyes commercial transition and growth

Cibus Inc's Q2 2023 performance reflects increased expenses and a net loss, with a focus on commercial transition.
Strengths lie in the efficient Trait Machine process, optimistic market outlook, and strategic collaborations.
Challenges include financial uncertainties, regulatory complexities, and balancing R&D with commercial goals.
Opportunities encompass product expansion, technology extension, M&A potential, and favorable market regulations.

Cibus Inc transitions to commercial focus with promising trait developments

Cibus Inc is transitioning to a commercial focus with promising trait developments in major crops.
Despite a net loss in Q3 2023, the company remains optimistic about future growth opportunities.
Regulatory advancements and strategic realignment position Cibus for potential market expansion.

Cibus Inc excels in gene editing transition, eyes industry growth

Cibus Inc's Q4 performance showcased successful transition, strong market focus, and strategic financial management.
While facing challenges related to merger impacts and spending adjustments, the company remains optimistic about growth opportunities.
With a clear vision for innovation and market leadership, Cibus is poised for continued success in the gene editing agricultural sector.

Cibus Inc (CBUS) reports strong Q1 performance amidst gene editing advancements

Cibus Inc (CBUS) had a strong Q1 2024 performance with revenue exceeding expectations, driven by increased customer demand. The company is navigating challenges in market penetration and increased expenses but sees opportunities in regulatory advances and advancing their gene editing platforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.

Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus' First Gene Edited Weed Management Solution for U.S. Rice Growers

Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development

Cibus and Biographica Announce Collaboration Using Artificial Intelligence (AI) to Advance Disease Resistance in Canola and Oilseed Rape

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference.

Cibus to Participate in the 13th Annual Roth Technology Conference

Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Cibus, Inc. (CBUS) Q3 2024 Earnings Call Transcript

Cibus (CBUS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.90 per share. This compares to loss of $1.59 per share a year ago.

Cibus (CBUS) Q3 Earnings and Revenues Top Estimates

Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development

Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024

The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola

Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call

Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20% Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20%

Cibus Inc. Announces Realigned Organization to Advance its Commercial Opportunities

SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, has been named a finalist for the Euroseeds2024 InnovActor Award and will have its technology showcased on the InnovAction Stage at the Euroseeds2024 Congress. Cibus' presentation will be given by Dr. Jim Radtke (SVP Product Development) who was recently honored by the American Seed Trade Association (ASTA) with a Lifetime Achievement Award. The event will take place in Copenhagen, Denmark, October 13-16 with the winner named at the 2024 InnovActor Ceremony on October 15.

Cibus Technology to be Featured on InnovAction Stage at the Euroseeds2024 Congress

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced that Peter Beetham, Co-Founder, President and Chief Operating Officer, will participate in a panel discussion titled “Sowing Solutions: Innovations in Climate-Resilient Seeds” at the Food+ Forum during the 79th session of the United Nations General Assembly (“UNGA”) in New York, NY, on Thursday, September 26, at 12:50 pm ET.

Cibus to Participate in the Food+ Forum during the 79th Session of the United Nations General Assembly

SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) at a public offering price of $4.00 per share. The Company has granted the underwriters a 45-day option to purchase an additional 450,000 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the offering are to be sold by the Company.

Cibus Announces Pricing of Public Offering of Class A Common Stock

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock in an underwritten public offering. Cibus also expects to grant to the underwriters of the offering a 45-day option to purchase up to an additional 15% of the shares of Class A common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Certain existing institutional and accredited investors and Rory Riggs, Cibus' Chief Executive Officer, have indicated an interest in purchasing shares of Class A Common Stock in this offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain existing investors and Mr. Riggs may elect not to purchase any shares in this offering, or the underwriters may elect not to sell any shares in this offering to those certain existing investors or Mr. Riggs.

Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock

Initial data from Pod Shatter Reduction field trials show promising results The first gene edited trait to complete field trials in oilseed rape in the UK SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has completed initial field tests of its Pod Shatter Reduction (PSR) trait in the United Kingdom.

Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced its participation in the following August investor events.

Cibus to Participate in Upcoming August Investor Events

Cibus, Inc. (NASDAQ:CBUS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Nick Anderson - ROTH Capital Matthew Venezia - Alliance Global Partners Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Steve Byrne - Bank of America Operator I'd like to turn the conference over to Wade King, Chief Financial Officer.

Cibus, Inc. (CBUS) Q2 2024 Earnings Call Transcript

Cibus (CBUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $3.05 per share a year ago.

Cibus (CBUS) Reports Q2 Loss, Tops Revenue Estimates

Early results of a novel weed management solution using two herbicides show promise. The first known use of stacked gene edited herbicide tolerant traits in an elite variety of rice  to improve weed management.

Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report second quarter 2024 financial results on Thursday, August 8, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Cibus to Report Second Quarter 2024 Financial Results on August 8, 2024 After the Market Close and Host Conference Call

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) --  Pomerantz LLP is investigating claims on behalf of investors of  Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS

NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

ATTENTION Cibus, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

CBUS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cibus, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

News for Cibus Inc Stock (CBUS)